1,295 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ... http://www.gurufocus.com/news/492165/perceptive-advisors-llc-buys-neurocrine-biosciences-aclaris-therapeutics-galapagos-nv-sells-dexcom-aerie-pharmaceuticals-depomed Mar 14, 2017 - Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells DexCom, Aerie Pharmaceuticals, Depomed, Stocks: NBIX,ACRS,FOLD,ANIP,AVXS,GBT,GLPG,AVDL,ACOR,IRTC,C, release date:Mar 14, 2017
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy http://www.zacks.com/stock/news/252712/novartis-breast-cancer-drug-okd-by-fda-as-first-line-therapy?cid=CS-ZC-FT-252712 Mar 14, 2017 - Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction http://www.zacks.com/stock/news/252531/aerie-resubmits-rhopressa-nda-roclatan-gains-traction?cid=CS-ZC-FT-252531 Mar 13, 2017 - Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.
How Incyte Stock Became a Bull Market Star for Biotech Investors http://www.zacks.com/stock/news/252365/how-incyte-stock-became-a-bull-market-star-for-biotech-investors?cid=CS-ZC-FT-252365 Mar 10, 2017 - Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.
Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ... http://www.gurufocus.com/news/490792/perceptive-advisors-llc-buys-neurocrine-biosciences-aclaris-therapeutics-galapagos-nv-sells-dexcom-aerie-pharmaceuticals-depomed Mar 09, 2017 - Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells DexCom, Aerie Pharmaceuticals, Depomed, Stocks: NBIX,ACRS,FOLD,ANIP,AVXS,GBT,GLPG,AVDL,ACOR,IRTC,C, release date:Mar 09, 2017
AMG Advanced Metallurgical Group NV reports Q4 results http://seekingalpha.com/news/3249819-amg-advanced-metallurgical-group-nv-reports-q4-results?source=feed_news_all Mar 09, 2017 - AMG Advanced Metallurgical Group NV (OTCPK:AMVMF): Q4 EPS of $0.32Revenue of $237.87M (+7.7% Y/Y)Press Release
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs http://www.zacks.com/stock/news/252108/trump-tweet-on-drug-pricing-hits-biotech-and-pharma-etfs?cid=CS-ZC-FT-252108 Mar 08, 2017 - President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara http://www.zacks.com/stock/news/252092/eli-lillys-taltz-shows-better-efficacy-than-jjs-stelara?cid=CS-ZC-FT-252092 Mar 08, 2017 - Eli Lilly and Company (LLY) announced superior efficacy in a head-to-head study evaluating its marketed drug, Taltz (ixekizumab) versus with Johnson & Johnson???s Stelara (ustekinumab) in patients with moderate-to-severe plaque.
David Winters Comments on Heineken Holding NV http://www.gurufocus.com/news/489875/david-winters-comments-on-heineken-holding-nv Mar 06, 2017 - David Winters Comments on Heineken Holding NV, Stocks: XAMS:HEIO, David Winters, release date:Mar 06, 2017
Gemalto NV 2016 Q4 - Results - Earnings Call Slides http://seekingalpha.com/article/4051831-gemalto-nv-2016-q4-results-earnings-call-slides?source=feed_all_articles Mar 03, 2017 - The following slide deck was published by Gemalto NV in conjunction with their 2016 Q4 earnings call.
<<<Page 121>